
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 2 | 6097.55 | 6100.00 | 10 |
| 2 | 6097.50 | 6101.35 | 7 |
| 9 | 6097.45 | 6101.50 | 4 |
| 11 | 6097.40 | 6102.05 | 2 |
| 1 | 6096.95 | 6102.55 | 4 |
| 9097 | Total | Total | 64667 |
| BUY | SELL | ||
|---|---|---|---|
| QTY | PRICE | PRICE | QTY |
| 2 | 6097.55 | 6100.00 | 10 |
| 2 | 6097.50 | 6101.35 | 7 |
| 9 | 6097.45 | 6101.50 | 4 |
| 11 | 6097.40 | 6102.05 | 2 |
| 1 | 6096.95 | 6102.55 | 4 |
| 9097 | Total | Total | 64667 |
As on --
(OI , PRICE )
As on --
Stock with good financial performance alongside good to expensive valuation
| Open | 6,124.95 |
| Previous Close | 6,134.90 |
| Volume | 220,756.00 |
| Value (Lacs) | 13,466.67 |
| VWAP | 6,078.28 |
| Beta | |
| Mkt Cap (Rs. Cr.) | 101,760 |
| High | 6,138.10 |
| Low | 6,023.20 |
| UC Limit | 6,748.35 |
| LC Limit | 5,521.45 |
| 52 Week High | 6,505.90 |
| 52 Week Low | 4,384.05 |
| Face Value | 5.00 |
| All Time High | 6,505.90 |
| All Time Low | 216.80 |
| 20D Avg Volume | 329,959 |
| 20D Avg Delivery(%) | -- |
| Book Value Per Share | 1,395.95 |
| Dividend Yield | 0.66 |
| TTM EPS See historical trend | 313.42 (+43.29% YoY) |
| TTM PE See historical trend | 19.46 (Low PE) |
| P/B See historical trend | 4.37 (Average P/B) |
| Sector PE | 53.19 |
*Delayed by 20 seconds.
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
| Days | |
|---|---|
| 5 | - - |
| 10 | - - |
| 20 | - - |
| 50 | - - |
| 100 | - - |
| 200 | - - |
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
| Days |
|---|
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | - - | - - | - - | - - | - - | - - | - - |
| Fibonacci | - - | - - | - - | - - | - - | - - | - - |
| Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| R1 | - - | Pivot - - |
S1 | - - |
| R2 | - - | S2 | - - | |
| R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
| Days |
|---|
| 1 Week | --% | |
| 1 Month | --% | |
| 3 Months | --% | |
| YTD | --% | |
| 1 Year | --% | |
| 3 Years | --% |
Strong India growth, benign price erosion in the US drive Q3 earnings for Indian pharma Mar 01 2024 03:09 PM
What are nutraceuticalsu00a0and why is government planning more regulationsu00a0around them? Feb 27 2024 10:03 AM
Dr Reddy's scales 52-week high on buzz over plans to acquire Novartis' India arm Feb 19 2024 01:15 PM
Dr. Reddy's eyeing to acquire Novartis' India arm: Report Feb 17 2024 03:01 PM
| Qty 31907 | Price 5645.45 | % Traded 0.02 |
| Qty 31907 | Price 5645.45 | % Traded 0.02 |
| Qty 20271 | Price 5355.2 | % Traded 0.01 |
| Qty 17456 | Price 5355.2 | % Traded 0.01 |
| Qty 1551 | Price 5355.2 | % Traded 0.00 |
| Qty 836 | Price 5355.2 | % Traded 0.00 |
| Qty 428 | Price 5355.2 | % Traded 0.00 |
| Qty 41157 | Price 5656.2 | % Traded 0.02 |
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
| Qty 884213 | Price 3076.83 | % Traded 0.53 |
| Qty 1547170 | Price 1479.21 | % Traded 0.93 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
| Qty 8215 | Price 5763.5 | % Traded 0.00 | Post Tnx Hold. 0.02% |
| Qty 230 | Price 5763.5 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 12090 | Price 5339 | % Traded 0.01 | Post Tnx Hold. 0.02% |
| Qty 5000 | Price 5327.45 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 2000 | Price 5817 | % Traded 0.00 | Post Tnx Hold. 0% |
| Qty 8304 | Price 5753.17 | % Traded 0.00 | Post Tnx Hold. 0% |
*Disclosures under SEBI Prohibition of Insider Trading Regulations, 2015
| Qty 3391906 | Price 0 | % Traded 2.03 | Post Tnx Hold. 5.59% |
| Qty 3424110 | Price 0 | % Traded 2.05 | Post Tnx Hold. 7.62% |
| Qty 3361696 | Price 0 | % Traded 2.01 | Post Tnx Hold. 9.69% |
| Qty 3386486 | Price 0 | % Traded 2.03 | Post Tnx Hold. 7.67% |
| Qty 3332456 | Price 0 | % Traded 2.00 | Post Tnx Hold. 5.64% |
| Qty 0 | Price 0 | % Traded 0.00 | Post Tnx Hold. 0% |
*Disclosures under SEBI SAST (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
| Date | Agenda |
|---|
| Ex-Date | Type | Dividend (Rs) |
|---|
| Announcement Date | Ex-Bonus | Ratio |
|---|
| Ex-Split | Old FV | New FV |
|---|
| Ex-Right | Ratio | Premium |
|---|
| Date | Agenda |
|---|
| Company Name | Price | % Chg | MCap(Cr) | TTM PE | P/B | ROE(%) | 1 Yr Perform(%) | Net Profit(Rs.) | Net Sales(Rs.) | Debt to Equity |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs | 6,100.05 | -0.57 | 101,756.86 | 19.46 | 4.37 | 19.35 | 37.41 | 4,470 | 24,669 | 0.05 |
| Sun Pharma | 1,550.75 | 0.15 | 372,076.87 | 41.78 | 6.64 | 15.13 | 61.33 | 8,560 | 43,885 | 0.11 |
| Cipla | 1,421.40 | -1.00 | 114,759.15 | 30.98 | 4.90 | 11.96 | 64.00 | 2,835 | 22,753 | 0.02 |
| Zydus Life | 961.05 | -0.91 | 97,277.88 | 32.71 | 5.55 | 11.19 | 101.82 | 2,001 | 17,237 | 0.07 |
| Divis Labs | 3,428.10 | -0.55 | 91,005.28 | 65.80 | 7.13 | 14.28 | 22.42 | 1,823 | 7,767 | 0.00 |